LM-second line treatment
PreclinicalSmall molecule
LM-second line treatment is one of 17 small molecule programs targeting Leptomeningeal Metastasis. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
16
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
20 competitors in Leptomeningeal Metastasis
#DrugCompanyPhaseTrials
1Cytosar
TevaApproved
Trexall
Jazz PharmaceuticalsApproved
Lenvima
EisaiApproved
Alimta
SShawn Eagle
Phase 2
Tepadina
Jazz PharmaceuticalsPhase 2
Intrathecal Chemotherapy
PPrincess Maxima Center for Pediatric Oncology
Phase 3
Furmonertinib
AAllist Pharmaceuticals, Inc.
Phase 2
Cadonilimab
SShanghai Pharmaceuticals Holding Co., Ltd
Phase 2
AK112
SSummit Therapeutics
Phase 2
QL1706
Qilu Pharmaceutical Co., Ltd.Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for LM-second line treatment. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- HHenan Cancer Hospital